Moderna, Inc. (MRNA)

mRNA vaccine maker, 4,700 full-time in 18 countries. Read October 20, 2026 from the annual report for the period ending December 31, 2025, filed February 20, 2026. Ranked 69 of the 110 Healthcare companies read so far, by the share within reach now.

The filing states 4,700 full-time employees in one mRNA medicines business with nothing counted by function or country, so one pharmaceutical pattern carries the workforce.

The figures on this page come from the company's own annual report and from BLS staffing patterns for its industries, never from a roster. They are estimates with a stated method. Nothing here says what the company will do: within reach is not a forecast of jobs lost or of savings.

What follows from the reading

Share of working time within reach of AI, on the long-run pace at four in five: 19% now, 34% at the end of 2027, 41% at the end of 2028, 44% at the end of 2030. By the patterns, the work is about 44% desk work, 14% people work and 42% body work. These are the site's industry estimates weighted by the shares below: estimates with a stated method and range, not a forecast of what the company will do. By the same patterns, at the end of 2028 about 57% of the working time stays with people (conversation, in-person and hands-on work), 36% becomes checking a model's work and 4% could be handed over with lighter checks, from the industries' own figures, not the company's roles.

Headcount

4,700 employees as of December 31, 2025 (stated). The filing counts no employees by country; it reports on U.S. employees without a number, and the United States is 65% of revenue.

The filing: “We had approximately 4,700 full-time employees in 18 countries as of December 31, 2025.”

The workforce as industry patterns

What the filing says about the workforce: About 4,700 full-time employees in 18 countries, down from 5,800 a year earlier; 46% hold doctoral, medical, law or master's degrees; no collective bargaining agreement with the company, with statutory agreements for a few employees in France, Italy and Spain and a works council in Madrid; voluntary turnover about 11%.

Companies read with the same leading pattern

Other companies whose largest staffing pattern is also Pharmaceutical and Medicine Manufacturing, largest first, each read from its own annual report. Within reach now and at the end of 2028, long-run pace, four in five.

• Johnson & Johnson (JNJ, 140,800 employees)19% now, 39% by 2028
• Thermo Fisher Scientific Inc. (TMO, 125,000 employees)20% now, 49% by 2028
• Merck & Co., Inc. (MRK, 75,000 employees)19% now, 41% by 2028
• Pfizer Inc. (PFE, 75,000 employees)19% now, 41% by 2028
• AbbVie Inc. (ABBV, 57,000 employees)19% now, 41% by 2028
• Eli Lilly and Company (LLY, 50,000 employees)19% now, 41% by 2028
• Bristol-Myers Squibb Company (BMY, 32,500 employees)19% now, 41% by 2028
• Amgen Inc. (AMGN, 31,500 employees)19% now, 41% by 2028

What the filing says about AI

36 sentences in the filing name AI. The filing says the company plans to leverage AI and digital tools for cost efficiency, uses AI and machine learning algorithms to optimize mRNA sequences, and runs an AI Academy to put AI into every system and process.

• “We plan to leverage our global production network, artificial intelligence (AI) and digital tools to improve cost efficiency. 3.”
• “In addition, multiple integrated algorithms that leverage artificial intelligence and machine learning optimize manufacturability, reduce failures and increase quality of mRNA sequences.”
• “We leverage third-party wholesalers and integrate with artificial intelligence-driven data analytics to ensure successful ordering and delivery.”
• “DIGITAL AND AI STRATEGY Since our founding, we have been a digital-first company, seeking to use the power of digital information to maximize our impact on patients. mRNA is an information molecule, and our company was built on the premise that the natural flow of information in life can be used to develop medicines.”
• “Leveraging over a decade of experience developing mRNA medicines, we have built a large library of data that, combined with our platform approach and cloud-native infrastructure, positions us well to scale a digital operating model using artificial intelligence (AI).”

Its annual reports, year by year

Sentences naming AI in each annual report, counted by one rule, beside the median report in the Index that year. Each count links its filing. Every company, by year and sector

• Fiscal 20219median 0
• Fiscal 20228median 0
• Fiscal 202324median 1
• Fiscal 202428median 4
• Fiscal 202536median 10

Headcount by filing year

As reported in each year's annual report, with the filing. A year marked not read had no figure the reading could take from the report's text.

Limits of this reading

• The filing counts full-time employees and states no other count.

Source: the company's annual report on EDGAR, accession 0001682852-26-000033, the filing. Read by Claude Fable 5.1 under rubric version 1, by the method. A company can write to info@stratussc.com to have its reading checked against its filing.